ArticleFrontiers in psychology2018
Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study.
Article in Frontiers in psychology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05698095 (A Phase 1, First-in-human, Double-blind, Placebo-controlled, Randomized, Single- and Multiple-ascending-dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine), which is not on this map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1, First-in-human, Double-blind, Placebo-controlled, Randomized, Single- and Multiple-ascending-dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) Administered by Intramuscular Injection in Healthy Subjects
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Dose-response relationships of psilocybin-induced subjective experiences in humans.Journal of psychopharmacology (Oxford, England) · 2021Pooled it
- Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults.Scientific reports · 2025Trial
- Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- The working lives of neuronal 5-HTRSC chemical biology · 2026Review
- Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review.Psychedelic medicine (New Rochelle, N.Y.) · 2026Article
- Vigilance state dissociation induced by 5-MeO-DMT in mice.Communications biology · 2026Article
- Roland R. Griffiths, psychopharmacology pioneer: Abuse liability, alcohol, nicotine, caffeine, benzodiazepines, and psychedelics.Journal of psychopharmacology (Oxford, England) · 2026Review
- On the meaning of "plasticity" in neuroscience and mental health research and its relation to the action of psychedelic therapy.Frontiers in neuroscience · 2026Article
- Acute experiences and persisting psychological effects associated with an encapsulated DMT-harmala alkaloid combination: results of a phase 1 study.Scientific reports · 2025Article
- 5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?Psychopharmacology · 2025Review
- Epidemiological patterns and therapeutic approaches of toad toxin poisoning in a retrospective case study.Scientific reports · 2025Review
- Evaluation of the peak experience scale as a rapid assessment tool for the strength of a psychoactive experience with 5-MeO-DMT.Frontiers in psychology · 2025Article
- Validation of the imperial psychedelic predictor scale.Psychological medicine · 2024Article
- The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action.Addiction biology · 2024Review
- Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.ACS medicinal chemistry letters · 2024Article
- Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics.Journal of psychopharmacology (Oxford, England) · 2024Review
- Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry.Psychedelic medicine (New Rochelle, N.Y.) · 2023Review
- 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Article
- Psilocybin's effects on cognition and creativity: A scoping review.Journal of psychopharmacology (Oxford, England) · 2023Article
- This is your brain on death: a comparative analysis of a near-death experience and subsequent 5-Methoxy-DMT experience.Frontiers in psychology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 1 country.
Funding
Abstract
5-MeO-DMT is a psychoactive substance found in high concentrations in the bufotoxin of the Colorado River Toad (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.